Drug Profile
Research programme: psoriasis therapies - GroPep
Alternative Names: pp 0102; PP-0102Latest Information Update: 04 Feb 2011
Price :
$50
*
At a glance
- Originator Northern Sydney Health
- Class Peptides
- Mechanism of Action T cell activation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Psoriasis
Most Recent Events
- 04 Feb 2011 Discontinued - Preclinical for Psoriasis in Australia (Topical)
- 21 Mar 2006 PP 0102 is available for licensing (http://www.gropep.com.au)
- 31 Dec 2003 Preclinical trials in Skin disorders in Australia (Topical)